Keith Chappell
0000-0001-8636-5067
University of Queensland
6 papers found
Refreshing results…
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
A broadly protective antibody that targets the flavivirus NS1 protein
Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2
Bacterial colonization dynamics associated with respiratory syncytial virus during early childhood
Analysis of phylogenetic diversity and in vitro adherence characteristics of respiratory syncytial virus and Streptococcus pneumoniae clinical isolates obtained during pediatric respiratory co-infections
Fighting Ebola: a window for vaccine re-evaluation?
Missing publications? Search for publications with a matching author name.